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REVIEW
New developments in the pharmacotherapeutic management of heart failure in
elderly patients: concerns and considerations
Elles M. Screever, Wouter C. Meijers, Dirk J. van Veldhuisen and Rudolf A. de Boer
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
ABSTRACT
Introduction: Heart failure (HF) remains a major public health problem worldwide, affecting approxi-
mately 23 million patients, and is predominantly a disease of the elderly population. Elderly patients
mostly suffer from HF with preserved ejection fraction (HFpEF), which often presents with multiple co-
morbidities and they require multiple medical treatments. This, together with the heterogeneous
phenotype of HFpEF, makes it a difficult syndrome to diagnose and treat.
Areas covered: Although HF is most abundant in the elderly, this group is still underrepresented in
clinical trials, which results in the lack of evidence-based medical regimens. The current review has
focused on new potential therapies for this poorly studied population. The focus will be on several
classes of drugs currently recommended or might be expected soon. These will include sacubitril/
valsartan (former LCZ696), Omecamtiv mecarbil, Vericiguat, Ivabradine, mineralocorticoid receptor
antagonists (MRAs) and potassium binders.
Expert opinion: We discuss promising new treatments and hypothesize that personalized approaches
will be needed to treat elderly patients optimally. Medical doctors should not only focus on HF therapy,
but comorbidities and polypharmacy should also influence therapeutic decision making. Furthermore,
the importance of quality of life as a management endpoint should not be underestimated in the frail
elderly.
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Heart failure (HF) is a detrimental disease, affecting approxi-
mately 23million patients worldwide [1]. It is a clinical syndrome,
accompanied by typical symptoms like shortness of breath,
orthopnea, ankle edema and fatigue, and signs like elevated
jugular venous pressure, pulmonary crackles, and a third heart
sound [2]. These signs and symptoms are caused by a structural
and/or functional cardiac abnormality. HF is associated with high
morbidity and mortality rates as well with frequent hospitaliza-
tion which have a huge impact on quality of life [3]. Even though
the cardiac treatment options have improved in the recent years,
it remains to be linked to a poor prognosis of 50% mortality
within 5 years [2]. In this review, we will focus on new potential
therapies that might improve outcome or reduce symptoms. We
aim to discuss therapeutic options in the ageing population.
HF also drives the burden on health insurance in developed
western countries. This is mostly due to a high 30-day rehos-
pitalization rate [4]. The US healthcare system current policy is
to fine hospitals in which a HF patient is rehospitalized prior to
30 days after initial discharge [5]. HF doctors are therefore
focused on identifying patients at risk, to prevent this phe-
nomenon. In all probability, the overall incidence and preva-
lence of HF will continue to rise, resulting in even higher
healthcare expenditures [6]. Beside pressure on healthcare,
the World Health Organization (WHO) well defined another
issue: ‘Population ageing is a triumph of humanity but also a
challenge to society’ [7]. Practically everywhere in the world,
the number of people older than 80 years is growing faster
than any other age group. As expected by the WHO, the
elderly population will increase in threefold in the upcoming
years [8]. This implicates that we will be confronted with an
elderly epidemic and their inherent problems (Figure 1).
1.1. HF in the elderly population
HF occurs mainly in the elderly population. Old patients
(≥65 years) account for 80% of HF hospitalizations and 90%
of HF-related deaths [9]. A lifetime risk of already 20% exists in
healthy 40-year-old subjects to develop HF. At the age of 80,
this risk remains unchanged, despite the fact elderly have a
much shorter life expectancy [10]. In addition, men have a
higher probability to develop HF compared to women, though
more women suffer from HF as a result of population demo-
graphics. The HF incidence rates of men nearly double every
10 years from the age of 65 and the incidence rates of women
even triple [10]. A higher incidence of HF in the elderly popu-
lation can be explained to a large extent by the normal ageing
process. Ageing results in cardiovascular changes, which may
ultimately increase the risk of HF development [11]. This
underscores that the prevalence of HF will increase substan-
tially due to ageing as well to developed drugs, which enable
increased survival [12,13].
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The prolonged life expectancy as well as the improved treat-
ment options for sudden cardiac death and coronary artery
disease (CAD) will result in a strong increase of newly diagnosed
HF patients. In addition, the worldwide prevalence of diabetes
and uncontrolled hypertension, which are major risk factors for
HF development and progression, might lead to an even stron-
ger increase in the number of HF patients [14]. In conclusion, HF
in the elderly differs clinically in many aspects from HF in the
relatively young population. For example in the elderly (1) HF
with preserved ejection fraction (HFpEF) is more common [15] (2)
often multiple comorbidities are present [16] and (3) most have
polypharmacy (≥5 medications) [17]. However, it is important to
note that a difference in terminology exists about the word
‘elderly’. Patients aged 65 probably have different characteristics
than patients aged 75. The TRITON-TIMI study (prasugrel vs.
clopidogrel in patients with acute coronary syndromes) [18]
showed less clinical efficacy and higher absolute levels of bleed-
ing in patients aged 75 years and older compared to the overall
cohort. The TRILOGY ACS investigators [19] even pre-adjusted
the prasugrel dose for patients aged 75 years and older, to
reduce possible bleeding adverse events. The results from the
TRITON-TIMI study are subgroup analyses. Multiple subgroup
analyses according to age will be mentioned in this review. Of
note, these data were obtained from post hoc analyses and
should be considered exploratory.
1.2. Differentiating in HF phenotype
As briefly mentioned above, HFpEF is more common in elderly
patients and the prevalence of HFpEF is increasing [15]. HF
characterization is mainly based on left ventricular ejection
fraction (LVEF). Therefore, HF can be classified into two main
subtypes. HF with reduced ejection fraction (HFrEF) and
HFpEF. HFrEF, also known as systolic HF, is characterized by
a lower-than-normal ejection fraction (LVEF <40%) due to
inadequate muscle wall contraction. While HFpEF patients
often have atrial fibrillation and hypertension in their history,
HFrEF patients often endured a myocardial infarction [2].
HFpEF, also known as diastolic HF, is a heterogeneous
syndrome both in the field of etiology and pathophysiology
and is characterized by a seemingly normal ejection fraction
(LVEF ≥50%). However, wall thickening may cause the ventri-
cle to hold an exceptionally small amount of blood. Due to
contributing factors, nonspecific signs and symptoms and the
absence of a dilated left ventricle, the HFpEF subtype is hard
to dissect [2]. A current review [20] clearly described the
clinical classification of HFpEF in which 7 subtypes could be
identified. These subtypes were atrial fibrillation, right HF
caused by pulmonary venous hypertension, CAD, hypertrophic
cardiomyopathy, multivalvular lesions, restrictive cardiomyo-
pathies, and finally the so-called ‘garden variety,’ which
includes hypertension, diabetes/metabolic syndrome, obesity
and/or chronic kidney disease. Although there is a lot of
controversy surrounding HFpEF and its subtypes, abovemen-
tioned clinical classification clearly indicates differences in
pathophysiology between HFpEF and HFrEF. HFpEF and
HFrEF also seem to have different etiological profiles: HFpEF
patients are generally older [21,22] and more often women
[22,23] compared to HFrEF patients.
According to the most recent European Society of
Cardiology (ESC) HF guidelines, the gray area between HFrEF
and HFpEF is classified as a third HF phenotype as the group
with a LVEF of 40–49%, also known as HF with mid-range
ejection fraction (HFmrEF). HFmrEF patients are likely to suffer
from mild systolic dysfunction together with characteristics of
diastolic dysfunction [2]. This also called middle child [24] is
currently under much investigation and might be depicted as
a transient between HFpEF and HFrEF. ‘Identifying HFmrEF as
a separate group will stimulate research into the underlying
characteristics, pathophysiology, and treatment of this group
of patients’, according to the most recent ESC HF guide-
lines [2].
In addition to the physical examination and the medical
history, biomarkers also showed to be indispensable tools in
establishing HF diagnosis and provide an estimate of prog-
nosis. Biomarkers are evaluated whether they could play a role
in disease management strategies [25]. The most studied and
established HF biomarkers are high-sensitivity troponin T
(hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-
proBNP) [26], which indicate myocyte injury and wall stress,
respectively. Although both markers are elevated in HF, HFrEF
patients tend to have higher levels compared to HFpEF.
Nevertheless, both yield a comparable prognostic value
regardless of LV ejection fraction [27]. Beside the diagnostic
and prognostic value of these biomarkers in HF management,
Article highlights
● The current dilemma is that HF is primarily a disease of the elderly
population. However, even though the major part of the HF cohort
consists of elderly patients, elderly are often underrepresented in
clinical trials.
● Diagnosing and treating HFpEF patients continues to be a challenge,
due to the heterogeneous phenotype, secondary comorbidities and
multiple medication and the associated lack of clarity of current
diagnostic criteria.
● Several novel medicaments, as discussed in this article, have been
studied in HFpEF patients and seem promising, although concrete
results for management of HFpEF are still lacking.
● Mortality and hospitalization are common study endpoints, while
elderly patients are likely to have different goals of treatment in
comparison with younger patients. Therefore, multidisciplinary
approaches mainly focused on quality of life instead of quantity of
life are a necessity to optimally treat elderly patients.
Figure 1. The increasing prevalence of the elderly population entails inherent
problems.




























it has been shown that biomarkers can be powerful in the
identification of new onset HF [28,29] and can also identify HF
patients with low risk of event [30]. Additionally, early HF
treatment based upon biomarker levels in patients with at
least one comorbidity has proven to reduce the HF incidence
[30–34]. Up until now, no concrete evidence to recommend
them for routine clinical use is in place [2]. Beside the estab-
lished biomarkers, novel biomarkers might add some incre-
mental value regarding differentiation between HFrEF and
HFpEF [35,36]. It has been suggested that the fibrosis marker
galectin-3 [36,37], suppression of tumorigenicity 2 (ST-2) [38],
and growth differentiation factor 15 (GDF-15) [39] might play a
prominent role in this phenotype distinction.
2 Therapeutic challenges in the elderly
Since elderly mainly suffer from the HFpEF phenotype, we
attempted in this review to primarily focus on treatment
options for HFpEF patients but also to provide an overview of
important conducted studies and ongoing trials. Unfortunately,
the established medical regimen in HFrEF patients has failed to
improve outcome in HFpEF. This includes angiotensin convert-
ing enzyme (ACE) inhibitors [40], angiotensin receptor blockers
(ARB)s [41], β-blockers [42], and digoxin [43]. This might be due
to the nonspecific symptoms, the heterogeneous phenotype,
and the lack of clarity regarding a well-defined definition of
HFpEF. Although, in a specific subgroup of elderly with chronic
HFpEF there is evidence that β-blockers might be of benefit
[44]. Beside medication, life style changes are also very impor-
tant in HF treatment. More than 70% of HFpEF patients suffer
from obesity [45], an independent risk factor for HF develop-
ment [46,47]. Despite the so-called ‘HF obesity paradox’ (obese
HF patients show lower mortality rates) [45], caloric restriction
diet seems to have beneficial effects in HFpEF patients [48]. The
same applies to aerobic exercise training, since exercise intoler-
ance is one of the primary symptoms of chronic HF [2].
According to the ESC, HF diagnosis is based on clinical
signs, chest X-rays and electrocardiograms (ECG) [2]. A retro-
spective study [49] with 116 old patients demonstrated that
the specificity of abovementioned methods is rather worse,
with only 50%, 20%, and 9%, respectively. Consequently, diag-
nosing HF in elderly is a difficult task and HF management
regarding HFpEF patients is solely symptomatic [50].
Despite the considerable prevalence of HF in the elderly,
elderly are often underrepresented in clinical trials. As can be
noted from Figure 2, clinical trials only examine a part of the
HF population compared to HF registries [51]. Further, elderly
have significantly worse outcomes compared to patients of
the younger generation [52]. Therefore, the importance of
studies to the efficiency and safety of recommended treat-
ments in elderly cannot be overemphasized.
Although limitations exist to study this specific population,
clinicians have to accept the fact that new therapeutic options
are a necessity to treat and manage these patients in the
future. The current review will focus on new medical treat-
ment options that are recently recommended or might be
expected soon. We will include sacubitril/valsartan (LCZ696),
omecamtiv mecarbil, vericiguat, ivabradine, MRAs, and potas-
sium binders (RLY5016) (for the mechanistic function see
Figure 3).
2.1. Sacubitril/valsartan – LCZ696
A hallmark in HF management is the renin-angiotensin-aldos-
terone system (RAAS) inhibition. The CONSENSUS trial in 1987
[53] already demonstrated the enormous benefit (40% mortal-
ity reduction) RAAS inhibition had on cardiovascular death.
The importance of RAAS inhibition was also observed in the
CHARM trial [54], in which the ARB candesartan resulted in a
survival benefit. The ELITE trial [55] showed in the elderly HF
patient that ARBs were better tolerated compared to ACE
inhibitors. In the (small) ELITE I study, treatment with ARBs
was associated with an unexpected reduction in mortality of
46% (losartan vs. captopril; 4.8% mortality vs. 8.7% mortality).
Prospectively, however, the (well-powered) ELITE II trial [56]
did not validate the superiority of losartan over captopril. But,
also in this study ARBs had a favorable safety profile compared
to ACE inhibitors. Recently, a combination therapeutic of the
angiotensin II receptor antagonist valsartan and the neprilysin
inhibitor sacubitril (LCZ696) has been studied, also known as
an angiotensin receptor-neprilysin inhibitor (ARNI) [57].
The PARAMOUNT study [57], a phase II randomized, dou-
ble-blind multicenter trial, studied the efficacy of sacubitril/
valsartan (n = 149) in HFpEF patients (LVEF >45%) compared
to valsartan (n = 152). Sacubitril/valsartan resulted after
12 weeks of treatment in reduced NT-proBNP levels compared
Figure 2. The elderly population is often underrepresented in clinical trials, while the majority of HF patients consists of elderly, as can be noted from the HF
registry.




























to valsartan and was also well tolerated in this study group.
Regarding secondary end points, sacubitril/valsartan did cor-
relate with left atrial reverse remodeling and showed a slightly
significant improvement regarding New York Heart
Association (NYHA) class after 36 weeks. Changes in NT-
proBNP were not significantly different in prespecified sub-
groups according to age (years): <65 (n = 207) and ≥65
(n = 59). However, in the elderly patients sacubitril/valsartan
may lead to lower NT-proBNP levels. Whether these effects
might translate into improved outcomes needs to be tested
prospectively. The PARAGON-HF study, recently announced,
will investigate the latter.
Expectations are high, because the PARADIGM-HF study
[58], a randomized, double-blind trial, in HFrEF patients (LVEF
≤40%) was terminated early because an overwhelming benefit
regarding sacubitril/valsartan was observed. On both end
points, cardiovascular mortality and HF hospitalization, sacubi-
tril/valsartan was proven to be superior to enalapril. The
PARADIGM-HF trial included a larger number of patients with
a broader range of ages compared to previous trials in HFrEF.
A sub-analysis of the PARADIGM-HF trial examined the
prespecified efficacy and safety outcomes according to age
category (years): <55 (n = 1624), 55–64 (n = 2655), 65–74
(n = 2557), and ≥75 (n = 1563). Although the rate of primary
end point increased across the age categories, LCZ696
remained to reduce the risk of an adverse event in all age
groups with an overall risk reduction of 20% [59]. The
PARADIGM-HF trial was designed to obtain evidence to sup-
port the replacement of ACE inhibitors or ARBs in the manage-
ment of chronic HF. Although this study implicates a greater
effect of sacubitril/valsartan compared to RAAS inhibitors, one
should keep in mind that sacubitril/valsartan treatment has
not been studied in comparison with an ARB alone.
Additionally, it has to be mentioned that the PARADIGM-HF
trial consisted of a single-blind run-in period during which all
patients received enalapril, followed by a single-blind run-in
Figure 3. Mechanism of function of new treatment options for HF. (a). The ARNI Entresto consists of the angiotensin II receptor antagonist valsartan and the
neprilysin inhibitor sacubitril. Valsartan inhibits binding of angiotensin II and sacubitril prevents breakdown of endogenous natriuretic peptides. Omecamtiv mecarbil
selectively activates cardiac myosin, resulting in increased myocardial contractility. Vericiguat stimulates sGC, resulting in production of cGMP and beneficial
cardiovascular effects through the PKG pathway. (b). Ivabradine specifically inhibits the If channel of the sinus node cells, resulting in reduction of the slow
depolarization action potential with decreased heart rate as a result. (c). MRAs function as antagonists of aldosterone in principal cells of the collecting duct,
preventing the effects of sodium retention, cardiac hypertrophy and cardiac fibrosis. (d). Potassium binders prevent intestinal potassium uptake by binding
potassium, thereby preventing a major problem in HF; hyperkalemia. Abbreviations: Aldo, aldosterone; Ang-II, angiotensin II; ANP, A-type natriuretic peptide; ARB,
angiotensin-receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AT1, type-1 angiotensin II receptor; BNP, B-type natriuretic peptide; cGMP, cyclic
guanosine monophosphate; CNP, C-type natriuretic peptide; GTP, guanosine-5ʹ-triphosphate; If channel, funny channel; K+, potassium; MR, mineralocorticoid
receptor; MRA, mineralocorticoid receptor antagonist; Na+, sodium; NO, nitric oxide; PKC, protein kinase C; PKG, protein kinase G, sGC, soluble guanylate cyclase.




























period during which all patients received LCZ696. This was
done to ensure an acceptable side effect profile, but also
constitutes a selection bias: Only eligible patients could con-
tinue the study, while elderly HF patients might be more
susceptible to suffer from side effects and might be excluded
based on these side effects.
Besides the PARAGON-HF, also two other trials are being
conducted with sacubitril/valsartan namely (1) PARADISE-MI, a
randomized, double-blind trial, which will investigate the effi-
cacy and safety of sacubitril/valsartan in patients with acute
myocardial infarction compared to ramipril and (2)
TRANSITION, a randomized single-blind study, which will com-
pare predischarge and post-discharge treatment with sacubi-
tril/valsartan in HFrEF patients hospitalized for acute
decompensation. In contrast to the above-described trials,
the PARAMETER study (ARNI vs. ARB) [60,61] specifically
focused on the elderly population (aged ≥60 years). The effi-
cacy of sacubitril/valsartan in patients with essential hyperten-
sion (SBP ≥150 to <180) was studied. Primary and secondary
end points included changes in central aortic systolic pressure
(CASP) and central aortic pulse pressure (CAPP) after 12 weeks
of treatment. Sacubitril/valsartan showed to be superior to
olmesartan in reducing both CASP and CAPP in high-risk
older patients.
2.2. Omecamtiv mecarbil
In HF patients, myocardial contractility is impaired. Several
pharmaceuticals [62–66] are developed to improve this con-
tractility, by increasing the intracellular calcium levels. Extra
calcium results in an increased force and velocity of contrac-
tion, but increased myocardial oxygen consumption is needed
to actively transport the calcium back into the sarcoplasmic
reticulum. Furthermore, the elevations in intracellular calcium
can increase the risk of arrhythmia [63]. A possible therapeutic
candidate is omecamtiv mecarbil (OM) because it is not
focused on increasing the calcium levels in cardiomyocytes.
OM is specifically designed to increase myocardial contracti-
lity, as a new selective cardiac myosin activator. OM acceler-
ates the transition of cross-bridges between myosin and actin
filaments and therefore mainly has an effect on the duration
of systole instead of ventricular pressure [67], which has been
proven by Teerlink et al. in a study with 34 healthy men in
2011 [68].
Cleland et al. [69] studied the safety, tolerability, and effi-
cacy of OM in patients with stable chronic systolic HF (LVEF
≤40%) in a double-blind phase II trial. Patients (n = 45)
received infusions with different doses of OM or placebo.
OM showed both a dose-dependent as well as a concentra-
tion-dependent increase in duration of systole and increased
stroke volume. In addition, the ATOMIC-AHF investigators [70]
evaluated the efficacy and safety of intravenous OM treatment
in patients with systolic dysfunction (LVEF ≤40%) who were
admitted with acute symptoms of HF. The primary efficacy
end point was the improvement of dyspnea. Secondary out-
comes of interest evaluated changes in NT-proBNP, incidence
of worsening HF, and short-term clinical outcomes. No
improvement regarding both the primary and secondary end
points was observed. Although OM showed a significant
increase in LV systolic ejection time, an increase in stroke
volume could not be observed. Nevertheless, OM was found
to be well tolerated and showed a trend toward dyspnea
improvement in the high-dose group.
In addition to intravenous OM treatment studies, the
COSMIC-HF trial [71] investigated oral OM treatment in a
randomized, double blind phase II safety/efficacy study in
patients with chronic HF and LV systolic dysfunction (LVEF
≤40%). Enrolled patients were randomized in either a fixed-
dose regimen (n = 150) or dose based upon pharmacokinetics
(n = 149). Efficacy endpoints included systolic ejection time,
left ventricular end-systolic and end-diastolic diameters, heart
rate, stroke volume and plasma concentration of NT-proBNP.
Pharmacokinetic-titration based on plasma concentrations
showed significant improvement regarding systolic ejection
time, stroke volume and LV fractional shortening after
24 weeks of treatment compared to placebo.
Contractility issues might also be of importance in HFpEF,
since Paulus et al. [72] described a new paradigm in HFpEF
development. High prevalence of comorbidities can induce a
systemic proinflammatory state, resulting in structural and
functional alterations of the myocardial tissue in which the
protein titin plays a major role. Based on this hypothesis, an
effect of OM may also be anticipated in HFpEF patients.
2.3. Vericiguat
HF is associated with increased inflammation and vascular
dysfunction, accompanied by reduced nitric oxide (NO) levels,
which ensures vasodilation in healthy individuals by binding
its ‘receptor’ soluble guanylate cyclase (sGC) [73]. Vericiguat is
an oral sGC stimulator, which induces the production of the
second messenger cyclic guanosine monophosphate (cGMP).
HFpEF is associated with increased LV and peripheral vascular
wall stiffness and right and left ventricular diastolic dysfunc-
tion, which results in altered LV end-diastolic pressures and
ventricular relaxation. Since the cGMP pathway is an important
regulator of endothelial function, cardiac performance and
myocardial energetics, targeting the cGMP pathway provides
compelling rationale as a therapeutic option in HFpEF patients
[74,75]. Treatment with sCG stimulators might result in a
maximal sGC activation, despite submaximally active NO levels
in HF patients.
The SOCRATES study [76] consists of two multicenter, ran-
domized, double-blind, dose-finding phase II trials, namely
SOCRATES-REDUCED and SOCRATES-PRESERVED. The recently
published SOCRATES-REDUCED trial [77] examined the efficacy
and tolerability of vericiguat in patients with worsening
chronic HF after clinical stabilization and LVEF <45%. The
dose effect of vericiguat was examined based upon NT-
proBNP levels and this was considered as the primary end
point. 351 patients were randomized to different doses of
vericiguat or placebo. Vericiguat treatment showed to be
well tolerated, but failed to significantly reduce NT-proBNP
levels compared to placebo. However, vericiguat might still
be a promising agent. Prespecified secondary analyses
demonstrated a significant increase in LVEF after 12 weeks of
treatment with the 10-mg dose compared to placebo and the




























10-mg dose was also associated with a trend toward reduction
of clinical cardiovascular events. The SOCRATES-PRESERVED
trial studied the same end points in HFpEF patients (LVEF
≥45%). This study is finished, but study results have not
been published yet. The phase III VICTORIA trial
(NCT02861534), currently enrolling HFrEF patients, aims to
determine the efficacy of vericiguat compared to placebo on
cardiovascular death or HF hospitalization.
2.4. Ivabradine
Ivabradine (corlanor or procoralan) specifically inhibits the
funny (If) channel, which regulates pacemaker activity in the
sinoatrial node. Inhibition leads to reduction of the slow
depolarization action potential and thereby resulting in
decreased heart rate. As far as known, ivabradine does not
directly modify other cardiovascular parameters and, there-
fore, will not cause reduction of blood pressure, in contrast
to β-blockers [78,79].
The SHIFT trial [80], a randomized, double-blind, placebo-
controlled trial studied the efficacy of ivabradine treatment in
patients with HFrEF (LVEF ≤35%) compared to placebo.
Reduction in heart rate (approximately 15 bpm from a base-
line value of 80 bpm) by ivabradine resulted in an 18% relative
risk reduction of the primary end point, a composite of cardio-
vascular deaths and HF rehospitalization. Treatment with ivab-
radine was not significant different between elderly
(≥65 years) and the younger population (<65 years).
However, the younger patients seemed to have more benefit
from ivabradine. The SHIFT trial investigated symptomatic HF
patients, the BEAUTIFUL and SIGNIFY trial investigated sub-
jects with CAD. The BEAUTIFUL investigators [81] demon-
strated that ivabradine treatment does not result in better
outcome regarding the primary end point. This was a compo-
site of (1) cardiovascular death, (2) admission for acute myo-
cardial infarction, and (3) new onset or worsening HF in
patients enrolled with CAD and LVEF <40%. Although ivabra-
dine might be a therapeutic option, the randomized, double-
blind, SIGNIFY trial [82], which investigated the efficacy of
ivabradine in patients with stable CAD without clinical HF
(LVEF >40%) did not result in a reduced risk of cardiovascular
death or death from nonfatal myocardial infarction compared
to placebo regardless of age.
Kosmala et al. [83] proved that short-term ivabradine treat-
ment (n = 30) leads to improvement of exercise tolerance by
improvement of LV filling pressure in symptomatic patients
with HFpEF (LVEF ≥50%) compared to placebo (n = 31).
Because many HFpEF patients only show HF symptoms during
exercise, ivabradine treatment may be beneficial in HFpEF
patients. However, a randomized crossover study [84] exam-
ined the effect of ivabradine treatment on exercise capacity in
22 symptomatic HFpEF patients with objective evidence of
exercise limitation compared to placebo. Study results were
compared with 22 similarly treated matched asymptomatic
hypertensive volunteers. Change in VO2 peak was set as pri-
mary end point. Ivabradine treatment significantly worsened
the change in VO2 peak compared to placebo in HFpEF
patients and significantly reduced submaximal exercise capa-
city, which was determined by the oxygen uptake efficiency
slope. These results question the role of heart rate reduction in
improving symptoms in HFpEF patients.
2.5. Mineralocorticoid receptor antagonists
The physiological importance of aldosterone is indirect regula-
tion of blood volume and blood pressure by sodium retention.
However, aldosterone also plays an essential role in the patho-
genesis of HF [85]. By antagonizing aldosterone, mineralocorti-
coid receptor antagonists (MRAs) can prevent the
pathophysiological effects of sodium retention, cardiac hyper-
trophy and cardiac fibrosis [86]. At present, the success of several
MRAs has already been established in HFrEF. First, the RALES trial
[87] determined the efficacy of co-therapy with spironolactone in
patients with severe HF (LVEF ≤35%) compared to placebo. The
primary efficacy end point evaluated all-cause mortality and
secondary end points included cardiovascular death and hospi-
talization and change in NYHA class. Spironolactone treatment
proved to be successful in reducing the risk of all-cause mortality
(30% risk reduction) and prespecified secondary outcomes when
compared to placebo regardless of age.
Second, the EPHESUS investigators [88] studied the efficacy of
eplerenone treatment in addition to optimal treatment in a
multicenter, randomized, double-blind trial in patients with LV
dysfunction (LVEF ≤40%) after acute myocardial infarction.
Treatment with eplerenone led to reduction of overall mortality
(15% risk reduction) and to reduction of cardiovascular death
and hospitalization (13% risk reduction) in comparison with
placebo. Although not significant, younger patients showed a
tendency toward better outcome compared to elderly (p = 0.08).
Finally, the multicenter, randomized EMPHASIS-HF trial
[89,90] also investigated the effectiveness of eplerenone in
patients with systolic HF (LVEF ≤35%) and mild HF symptoms.
The EMPHASIS-HF only studied patients with an age above 55
and revealed a risk reduction in primary end point (combination
of cardiovascular death and HF hospitalization) by 37% and
additionally a reduction in the rate of death from any cause
and the rate of hospitalization for any reason compared to
placebo.
The last few years, there is also an increasing number of
studies suggesting a beneficial effect of MRAs in HFpEF
patients. In the Aldo-DHF trial [91], HFpEF patients (LVEF
≥50%) were randomized to spironolactone or placebo and
followed up for 12 months. Spironolactone treatment was
found to enhance diastolic function, but no significant differ-
ences were observed in maximal exercise capacity, HF symp-
toms or quality of life. However, in the Aldo-DHF trial, the
clinical significance of the improved LV function was not exam-
ined. The TOPCAT study [92], a randomized, double-blind,
phase III trial studied the efficacy of spironolactone in patients
with symptomatic HF and a LVEF of ≥45%. The primary end
point was a composite of cardiovascular death, aborted cardiac
arrest and HF hospitalization. Spironolactone treatment failed
to show significant reduction in primary outcome compared to
placebo. However, a post hoc analysis [93] showed a markedly
reduced rate of primary outcome, cardiovascular death and HF
hospitalization in the Americas, suggesting a beneficial effect of
spironolactone in elderly HFpEF patients.





























Hyperkalemia is a well-known problem in HF patients and is
associated with both mortality and hospitalization [94].
Especially elderly are vulnerable to hyperkalemia due to
decreased aldosterone production and cardiac therapy
[95,96], in which mainly RAAS inhibitors and MRAs play a
role. The fear for occurrence of hyperkalemia might result in
premature discontinuation of treatment or insufficient dosing
[97], resulting in increased cardiovascular risk. The current
therapy options for reducing potassium levels carry quite
some disadvantages like (1) patient adherence is low and (2)
current pharmaceuticals might have low tolerability and entail
unfavorable adverse effects [98]. In the light of this
knowledge, potassium binders, which can prevent intestinal
potassium uptake, may offer a solution.
RLY5016, which is also known as patiromer sorbitex cal-
cium, is the most studied potassium binder. In the past
50 years, RLY5016 is the first new drug approved for hyperka-
lemia treatment [99]. The PEARL-HF investigators [100] con-
ducted a randomized, double-blind trial, in which the efficacy
and safety of the potassium binder RLY5016 was investigated
in patients with chronic HF (LVEF ~40%). Patients were treated
with RLY5016 in addition to standard therapy, including an
ACE inhibitor or ARB and a β-blocker, resulting in significant
reduction of serum K+. As expected, RLY5016 has proven to
reduce the incidence of hyperkalemia and to increase the
number of patients which could be up-titrated with spirono-
lactone compared to placebo. On the other hand, RLY5016
treatment resulted, as could be expected, in more cases in
hypokalemia compared to placebo (6% vs. 0%).
3 Conclusion
A major concern for the next generation is the rise of elderly
people, and specifically elderly patients with HF. As discussed in
this review, most elderly HF patients can be characterized as
HFpEF patients. Diagnosing, treating, and managing patients
with HFpEF still remains a challenge. This is due to (1) the hetero-
geneous syndrome, (2) the associated lack of clarity of current
diagnostic criteria, (3) the absence of established treatment, (4) the
focus on HFrEF in most HF studies, and (5) the large discrepancy
between enrolled patients in HF trials and registries, as depicted in
Figure 2. Intervention, to (1) prevent disease development (2)
slowdown disease progression, (3) treat comorbid conditions, (4)
improve quality of life, and (5) reduce HF rehospitalizations and
cardiovascular death, should be a top priority for the upcoming
years. In summary, these observations imply that studies relating
novel therapeutic options for HFpEF are needed.
4 Expert opinion
In the last decades, the cardiology field has improved dramati-
cally, especially with improved re-synchronization therapy [101],
ventricular assist devices [102,103], and heart transplantation
[104]. Scientists assemble to keep improving at the same pace.
These new pharmaceuticals have been studied and seem pro-
mising, but concrete results for management of HFpEF are still
lacking. Nevertheless, we might need to accept that new
developed drugs will not be able to drastically reduce the pri-
mary end point of trials published in the 80s and 90s. Although
we need to strive for smaller goals, for example vericiguat, which
seemed a promising agent in HFrEF. Compared to placebo it
resulted in an increase in LVEF and a trend toward reduction of
clinical events. Although study results of vericiguat treatment in
HFpEF patients are likely to be published on short notice, no
current HFpEF trials are available at this moment. Also, not a
single HFpEF study to the efficacy of OM and the potassium
binder RLY5016 have been performed. Understanding the pro-
blems that we face, and the ‘lacks in our knowledge’ that cur-
rently exist, we are eager to hopefully see these kind of studies
emerging on a short notice. Intravenous OM showed an increase
in LV systolic ejection time and a trend toward dyspnea improve-
ment and oral OM showed improvement in systolic ejection
time, stroke volume, and LV fractional shortening, which all
might benefit HFpEF patients. Tackling side effects that prohibit
optimal uptitration of HF medication are also welcome. This
could be a possible role for potassium binders. These drugs
may be of great potential for elderly patients, as they are primar-
ily vulnerable for hyperkalemia due to reduced aldosterone
levels.
In contrast to the above-mentioned drugs, data are avail-
able of sacubitril/valsartan, ivabradine and MRAs in HFpEF
patients. Sacubitril/valsartan proved to be well tolerated and
showed an overwhelming advantage in cardiovascular mortal-
ity and HF hospitalization in HFrEF patients. Also in HFpEF
patients, sacubitril/valsartan appears promising. It was asso-
ciated with left atrial reverse remodeling and an improvement
in NYHA class. Additionally, the PARAMETER trial, which spe-
cifically focused on elderly, also showed positive results. We all
await the results of the prospective PARAGON-HF study which
will provide us with the evidence whether sacubitril/valsartan
will lead to improved outcomes in HFpEF patients.
Ivabradine treatment showed to reduce cardiovascular
deaths and HF rehospitalizations in HFrEF patients.
Additionally, ivabradine may also prove useful in HFpEF
patients, because of the proven increase in exercise tolerance.
Finally, in recent years, an increasingly amount of clinical trials
focused on the efficacy of MRAs in HFpEF patients and
showed beneficial effects.
4.1. Challenges ahead
Ageing results in age-related physiological changes, not all
cardiac related. Older HF patients often have to cope with
multiple comorbidities. These diseases might involve each
other, especially as hypothesized in HFpEF [72]. Additionally,
HF patients generally use multiple prescription drugs, up to 10
or 15 in one patient. Clearly the use of such combinations not
only raises the likelihood of simple side effects, but drug–drug
or drug–disease interactions are common and are often not
considered. Specifically, the use of nonsteroidal anti-inflamma-
tory drugs, antiarrhythmic drugs and statins is notorious when
it comes to drug interactions [105]. The heterogeneous phe-
notype of HFpEF is already a reason not to pursue the ‘one-
size-fits-all’ approach in HFpEF patients. Comorbidities and
polypharmacy make multidisciplinary approaches even more




























important to optimally treat elderly patients. For instance, age-
related decline in kidney function has been recognized for
decades, as reflected by estimated glomerular filtration rate
(eGFR) [106]. Coexistence of HF and poor renal function occurs
regularly and is associated with an extremely bad prognosis
[107]. Therefore, it can be very important to adapt therapy
dose to kidney function in treatment of elderly patients. We
report important indices of pharmacokinetics and influences
of kidney function in Table 1.
The balance between the treatment of comorbidities, but
simultaneously the relevance to be aware of polypharmacy is
delicate and therefore the medical regimen for a HF patient
has to be chosen wisely. Despite the complicated manage-
ment of HF in elderly, clinical trials still underrepresent these
typical HF patients. Furthermore, the exceedingly heteroge-
neous HFpEF phenotype might presumably contribute greatly
to the failure of randomized clinical trials in HFpEF patients.
Therefore, we would like to stimulate studies that shift the
focus more on the elderly population and make a better
differentiation between HFpEF phenotypes. Further, mortality
and hospitalization are common primary and secondary study
end points, while frail older patients are probably more inter-
ested in their functional capacity and quality of life. This
emphasizes the importance of life style changes in addition
to medical treatment. Taken together, personalized treatment
mainly aimed at quality of life instead of quantity of life, may
be a solution for the elderly population.
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